High Density Lipoproteins
Springer International Publishing
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Chapter title |
Antisense Oligonucleotides, microRNAs, and Antibodies.
|
|---|---|
| Chapter number | 22 |
| Book title |
High Density Lipoproteins
|
| Published in |
Handbook of experimental pharmacology, December 2014
|
| DOI | 10.1007/978-3-319-09665-0_22 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-909664-3, 978-3-31-909665-0
|
| Authors |
Alberto Dávalos, Angeliki Chroni, Dávalos, Alberto, Chroni, Angeliki |
| Editors |
Arnold von Eckardstein, Dimitris Kardassis |
| Abstract |
The specificity of Watson-Crick base pairing and the development of several chemical modifications to oligonucleotides have enabled the development of novel drug classes for the treatment of different human diseases. This review focuses on promising results of recent preclinical or clinical studies on targeting HDL metabolism and function by antisense oligonucleotides and miRNA-based therapies. Although many hurdles regarding basic mechanism of action, delivery, specificity, and toxicity need to be overcome, promising results from recent clinical trials and recent approval of these types of therapy to treat dyslipidemia suggest that the treatment of HDL dysfunction will benefit from these unique clinical opportunities. Moreover, an overview of monoclonal antibodies (mAbs) developed for the treatment of dyslipidemia and cardiovascular disease and currently being tested in clinical studies is provided. Initial studies have shown that these compounds are generally safe and well tolerated, but ongoing large clinical studies will assess their long-term safety and efficacy. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 31% |
| Student > Master | 4 | 15% |
| Student > Ph. D. Student | 3 | 12% |
| Student > Postgraduate | 2 | 8% |
| Other | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 4 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 27% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Agricultural and Biological Sciences | 4 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 15% |
| Social Sciences | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 3 | 12% |